Is NovaBay Pharmaceuticals Stock a Good Investment?
NovaBay Pharmaceuticals Investment Advice | NBY |
- Examine NovaBay Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research NovaBay Pharmaceuticals' leadership team and their track record. Good management can help NovaBay Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact NovaBay Pharmaceuticals' business and its evolving consumer preferences.
- Compare NovaBay Pharmaceuticals' performance and market position to its competitors. Analyze how NovaBay Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if NovaBay Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about NovaBay Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in NovaBay Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if NovaBay Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine NovaBay Pharmaceuticals Stock
Researching NovaBay Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was now reported as 0.22. The company recorded a loss per share of 74.61. NovaBay Pharmaceuticals had not issued any dividends in recent years. The entity had 1:35 split on the 31st of May 2024.
To determine if NovaBay Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NovaBay Pharmaceuticals' research are outlined below:
| NovaBay Pharmaceuticals had very high historical volatility over the last 90 days | |
| NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock | |
| NovaBay Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 14.73 M. Reported Net Loss for the year was (9.64 M) with profit before taxes, overhead, and interest of 5.64 M. | |
| NovaBay Pharmaceuticals has about 5.36 M in cash with (4.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07. | |
| NovaBay Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from businesswire.com: Renowned Ophthalmology Leaders to Join CellViva Board of Directors |
NovaBay Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
NovaBay Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NovaBay Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NovaBay Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact NovaBay Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises NovaBay Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.3 | -0.33 | -0.03 | 10 | ||
2023-08-10 | 2023-06-30 | -0.56 | -0.64 | -0.08 | 14 | ||
2024-08-13 | 2024-06-30 | -1.23 | -1.37 | -0.14 | 11 | ||
2022-08-11 | 2022-06-30 | -1.23 | -1.4 | -0.17 | 13 | ||
2021-03-25 | 2020-12-31 | -1.57 | -1.4 | 0.17 | 10 | ||
2021-11-11 | 2021-09-30 | -1.4 | -1.75 | -0.35 | 25 | ||
2020-05-07 | 2020-03-31 | -2.45 | -2.1 | 0.35 | 14 | ||
2019-03-28 | 2018-12-31 | -2.92 | -2.45 | 0.47 | 16 |
NovaBay Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a total capitalization of 2.77 M.Market Cap |
|
NovaBay Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.07) | (1.12) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (1.07) | (1.12) | |
| Return On Equity | (2.91) | (3.05) |
Determining NovaBay Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if NovaBay Pharmaceuticals is a good buy. For example, gross profit margin measures NovaBay Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NovaBay Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in NovaBay Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NovaBay Pharmaceuticals. Check NovaBay Pharmaceuticals' Beneish M Score to see the likelihood of NovaBay Pharmaceuticals' management manipulating its earnings.
Evaluate NovaBay Pharmaceuticals' management efficiency
NovaBay Pharmaceuticals has Return on Asset of (0.3867) % which means that on every $100 spent on assets, it lost $0.3867. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.6383) %, meaning that it generated no profit with money invested by stockholders. NovaBay Pharmaceuticals' management efficiency ratios could be used to measure how well NovaBay Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2024. Return On Capital Employed is likely to drop to -1.1 in 2024. At this time, NovaBay Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2 M in 2024, whereas Other Assets are likely to drop slightly above 461.6 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 27.52 | 26.14 | |
| Tangible Book Value Per Share | 27.52 | 26.14 | |
| Enterprise Value Over EBITDA | (0.10) | (0.10) | |
| Price Book Value Ratio | 0.26 | 0.25 | |
| Enterprise Value Multiple | (0.10) | (0.10) | |
| Price Fair Value | 0.26 | 0.25 | |
| Enterprise Value | 469.9 K | 446.4 K |
NovaBay Pharmaceuticals' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 0.732 |
Basic technical analysis of NovaBay Stock
As of the 18th of December 2024, NovaBay Pharmaceuticals secures the Mean Deviation of 4.28, risk adjusted performance of 0.06, and Downside Deviation of 4.46. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NovaBay Pharmaceuticals, as well as the relationship between them.NovaBay Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NovaBay Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on NovaBay Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NovaBay Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zheng Yongxiang over three months ago Acquisition by Zheng Yongxiang of 30000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Zheng Yongxiang over six months ago Acquisition by Zheng Yongxiang of 30000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Garlikov Julie over six months ago Acquisition by Garlikov Julie of 858 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Kunin Jeffrey over six months ago Acquisition by Kunin Jeffrey of 101650 shares of NovaBay Pharmaceuticals at 0.4625 subject to Rule 16b-3 | ||
Yenyou Zheng over six months ago Exercise or conversion by Yenyou Zheng of 30000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Mijia Wu over a year ago Acquisition by Mijia Wu of 858 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Mijia Wu over a year ago Exercise or conversion by Mijia Wu of 858 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 |
NovaBay Pharmaceuticals' Outstanding Corporate Bonds
NovaBay Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NovaBay Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NovaBay bonds can be classified according to their maturity, which is the date when NovaBay Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NOVARTIS CAPITAL P Corp BondUS66989HAS76 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAQ11 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAR93 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAP38 | View | |
| NOVARTIS CAP P Corp BondUS66989HAN89 | View | |
| NOVARTIS CAP P Corp BondUS66989HAK41 | View | |
| NOVARTIS CAP P Corp BondUS66989HAJ77 | View | |
| US66981QAA40 Corp BondUS66981QAA40 | View |
Understand NovaBay Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing NovaBay Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.06 | |||
| Market Risk Adjusted Performance | (0.60) | |||
| Mean Deviation | 4.28 | |||
| Semi Deviation | 3.65 | |||
| Downside Deviation | 4.46 | |||
| Coefficient Of Variation | 1423.8 | |||
| Standard Deviation | 7.68 | |||
| Variance | 59.03 | |||
| Information Ratio | 0.0614 | |||
| Jensen Alpha | 0.5801 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.1058 | |||
| Treynor Ratio | (0.61) | |||
| Maximum Drawdown | 58.17 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 9.86 | |||
| Downside Variance | 19.88 | |||
| Semi Variance | 13.32 | |||
| Expected Short fall | (6.96) | |||
| Skewness | 3.95 | |||
| Kurtosis | 22.39 |
| Risk Adjusted Performance | 0.06 | |||
| Market Risk Adjusted Performance | (0.60) | |||
| Mean Deviation | 4.28 | |||
| Semi Deviation | 3.65 | |||
| Downside Deviation | 4.46 | |||
| Coefficient Of Variation | 1423.8 | |||
| Standard Deviation | 7.68 | |||
| Variance | 59.03 | |||
| Information Ratio | 0.0614 | |||
| Jensen Alpha | 0.5801 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.1058 | |||
| Treynor Ratio | (0.61) | |||
| Maximum Drawdown | 58.17 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 9.86 | |||
| Downside Variance | 19.88 | |||
| Semi Variance | 13.32 | |||
| Expected Short fall | (6.96) | |||
| Skewness | 3.95 | |||
| Kurtosis | 22.39 |
Consider NovaBay Pharmaceuticals' intraday indicators
NovaBay Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NovaBay Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 8666.67 | |||
| Daily Balance Of Power | (1.60) | |||
| Rate Of Daily Change | 0.86 | |||
| Day Median Price | 0.52 | |||
| Day Typical Price | 0.51 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.08) |
NovaBay Stock media impact
Far too much social signal, news, headlines, and media speculation about NovaBay Pharmaceuticals that are available to investors today. That information is available publicly through NovaBay media outlets and privately through word of mouth or via NovaBay internal channels. However, regardless of the origin, that massive amount of NovaBay data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NovaBay Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NovaBay Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NovaBay Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NovaBay Pharmaceuticals alpha.
NovaBay Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards NovaBay Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NovaBay Pharmaceuticals Corporate Executives
Elected by the shareholders, the NovaBay Pharmaceuticals' board of directors comprises two types of representatives: NovaBay Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NovaBay. The board's role is to monitor NovaBay Pharmaceuticals' management team and ensure that shareholders' interests are well served. NovaBay Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NovaBay Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Jones | Chief Financial Officer, Treasurer | Profile |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.